Protein / target
DNA gyrase subunit A
Protein at a glance
Biological role
ATP-dependent activity, acting on DNA
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function
A type II topoisomerase that negatively supercoils closed circular double-stranded (ds) DNA in an ATP-dependent manner to maintain chromosomes in an underwound state (PubMed:12051842, PubMed:18642932, PubMed:186775, PubMed:19060136, PubMed:19965760, PubMed:20356737, PubMed:22457353, PubMed:23294697, PubMed:3031051, PubMed:7811004, PubMed:9148951). This makes better substrates for topoisomerase IV (ParC and ParE) which is the main enzyme that unlinks newly replicated chromosomes in E.coli (PubMed:9334322). Gyrase catalyzes the interconversion of other topological isomers of dsDNA rings, including catenanes (PubMed:22457352). Relaxes negatively supercoiled DNA in an ATP-independent manner (PubMed:337300). E.coli gyrase has higher supercoiling activity than many other bacterial gyrases; at comparable concentrations E.coli gyrase introduces more supercoils faster than M.tuberculosis gyrase, while M.tuberculosis gyrase has higher decatenation than supercoiling activity compared to E.coli (PubMed:22457352). E.coli makes 15% more negative supercoils in pBR322 plasmid DNA than S.typhimurium; the S.typhimurium GyrB subunit is toxic in E.coli, while the E.coli copy can be expressed in S.typhimurium even though the 2 subunits have 777/804 residues identical (PubMed:17400739). The enzymatic differences between E.coli gyrase and topoisomerase IV are largely due to the GyrA C-terminal domain (approximately residues 524-841) and specifically the GyrA-box (PubMed:16332690, PubMed:8962066)
Subcellular location
Domains and Gene Ontology detail (18)Hide
Domains & features
Gene Ontology
- Cchromosome
- Ccytoplasm
- Ccytosol
- CDNA topoisomerase type II (double strand cut, ATP-hydrolyzing) complex
- Cmembrane
- FATP binding
- FATP-dependent activity, acting on DNA
- FDNA binding
- FDNA negative supercoiling activity
- FDNA topoisomerase type II (double strand cut, ATP-hydrolyzing) activity
- Fidentical protein binding
- PDNA topological change
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Transcriptional regulation
- ·DNA-templated transcription
View underlying pathways (2)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Drugs targeting this protein
Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.
Bacterial DNA gyrase inhibitor
Bacterial DNA gyrase inhibitor
ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.
Show remaining trials (24)Hide
ClinicalTrials.gov via the drug-target graph.
What's happening now
Recent activity around this target, drawn from one canonical event stream. Every item is reached through 2 drugs that target this protein, so each event is news about that drug rather than about the protein directly.
- Industry developmentCatalytic degradation of ciprofloxacin via peroxymonosulfate activation using a UiO66 and amino functionalized silica coated magnetite composite
- Label change
Label change: CIPROFLOXACIN (ANDA076558)
- Label change
Label change: CIPROFLOXACIN (ANDA076794)
- Industry developmentAdsorption of ciprofloxacin onto engineered biochar derived from floating aquatic weed biomass with isotherm kinetic and interaction mechanism analysis
- New publicationCompatible co-administration of BioThrax® vaccine and ciprofloxacin-Results of a randomized open-label drug-vaccine interaction trial.
- New publicationGlobal diversity and antimicrobial resistance of typhoid fever pathogens: Insights from a meta-analysis of 13,000 <i>Salmonella</i> Typhi genomes.
- Label change
Label change: CIPROFLOXACIN (ANDA076558)
- Label change
Label change: CIPROFLOXACIN (ANDA076558)
- Label change
Label change: CIPROFLOXACIN (ANDA076558)
- Label change
Label change: CIPROFLOXACIN (ANDA076558)
- Label change
Label change: CIPROFLOXACIN (ANDA076558)
- Label change
Label change: CIPROFLOXACIN (ANDA076558)
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.